News about general reimbursement of medicines
-
Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups A04 (antiemetics and antinauseants) and A03FA (propulsives)
| 30 June 2009 |
At the Danish Medicines Agency’s request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC groups A04 (antiemetics and antinauseants) and A03FA (propulsives).
-
Reimbursement status of medicinal products in ATC groups A06 and A02AA04, laxatives: Consultation responses to the Reimbursement Committee's recommendation
| 04 June 2009 |
The Reimbursement Committee's recommendation on the future reimbursement status of laxatives (ATC groups A06 and A02AA04) has been open for consultation until 27 May 2009.
-
Reimbursement status of medicinal products in ATC group A08, antiobesity preparations, excl. diet products: Consultation responses to the Reimbursement Committee's recommendation
| 04 June 2009 |
The Reimbursement Committee's recommendation on the future reimbursement status of antiobesity preparations, excl. diet products (ATC group A08) has been open for consultation until 25 May 2009.
-
Consultation on the reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)
| 04 May 2009 |
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)
-
Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A08 (antiobesity preparations, excl. diet products)
| 30 April 2009 |
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group A08 (antiobesity preparations, excl. diet products).
-
Consultation responses on the future reimbursement status of 5 combination products in ATC groups C07, C08 and C09
| 02 February 2009 |
The Danish Medicines Agency's assessment of the future reimbursement status of 5 combination products in ATC groups C07, C08 and C09 for the treatment of cardiovascular diseases has been submitted for consultation with 11 December 2008 as the consultation deadline.
-
Consultation responses on the future reimbursement status of dihydropyridine calcium antagonists (C08CA)
| 19 December 2008 |
The Danish Medicines Agency's assessment of the future reimbursement status of the dihydropyridine calcium antagonists (C08CA) were submitted for consultation with 11 November 2008 as the consultation deadline.
-
Reassessment of reimbursement status for 5 combination products in ATC groups C07, C08 and C09
| 27 November 2008 |
The Danish Medicines Agency has assessed the question of the future reimbursement status for five combination products in ATC groups C07, C08 and C09 on the basis of updated information about prices and consumption of these medicinal products.
-
Consultation responses on the future reimbursement status of medicinal products for cardiovascular diseases
| 21 November 2008 |
The Reimbursement Committee’s additional recommendation concerning the future reimbursement status of medicinal products for cardiovascular diseases in ATC groups C02, C03, C07, C08 and C09 (antihypertensives) was submitted for consultation with 19 September 2008 as the consultation deadline
-
Reassessment of reimbursement status for medicinal products in ATC group C08CA
| 29 October 2008 |
The Danish Medicines Agency has assessed the question of the future reimbursement status for medicinal products in ATC group C08CA (dihydropyridine calcium channel blockers) which are used for the treatment of cardiovascular diseases.
-
Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee
| 08 September 2008 |
The Danish Medicines Agency has asked the Reimbursement Committee to reassess the reimbursement status of medicinal products authorised for marketing in Denmark in the ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).
-
Consultation responses to the recommendation about the reimbursement status for medicinal products for the treatment cardiovascular diseases
| 07 July 2008 |
The Reimbursement Committee's recommendation about the future reimbursement status of medicinal products for the treatment of cardiovascular diseases in ATC groups C02, C03, C07, C08 and C09 (antihypertensive drugs) was submitted for consultation on 5 May 2008.
-
Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases
| 14 February 2008 |
Following a request from the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status for medicinal products authorised for marketing in Denmark in ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).
-
Reassessment of the reimbursement status of blood pressure products resumed in the Reimbursement Committee
| 23 May 2007 |
At its meeting on 12 December 2006, the Reimbursement Committee resumed the reassessment of the reimbursement status of blood pressure products.
-
New reimbursement status of lipid lowering medicinal products enters into force on 23 April 2007
| 29 March 2007 |
As of 23 April 2007, the reimbursement status of lipid lowering medicinal products will be changed. The decision includes all lipid lowering medicinal products with marketing authorisations in Denmark on 15 March 2007.
-
Reassessment of reimbursement status of medicinal products in ATC-groups A01, A04, C04, C05 and C10
| 15 February 2007 |
In connection with the reassessment of the reimbursement status of medicinal products, the Reimbursement Committee discussed the reimbursement status of certain ATC groups at its meeting on 16 January 2007.
-
Reassessment of reimbursement status for medicinal products for hypertension
| 18 December 2006 |
In March 2006, the Danish Medicines Agency contacted a number of scientific societies to clarify certain aspects of the treatment of hypertension in Denmark.
-
Reassessment of reimbursement status of the remaining subgroups of ATC group C
| 18 December 2006 |
The Danish Medicines Agency previously notified companies and a number of scientific societies and patient organisations about which ATC groups and subgroups would be the first to be reassessed, cf. the fact box to the right.
-
Reassessment of ATC-groups C01, C04 and C05
| 18 December 2006 |
At its meeting on 19 September 2006, the Reimbursement Committee had its first discussion of the reimbursement status of the following ATC groups.
-
Reassessment of reimbursement status of ATC-groups C01, C04 and C05
| 18 December 2006 |
At its meetings on 19 September and 7 November 2006, the Reimbursement Committee discussed the reimbursement status of medicinal products in ATC-groups.